Article Copyright: Simon Elmer at Architects for Social Housing. A long but informative read. From Development to Approval At the end of November, it was revealed that the Oxford Vaccine Group had conducted the clinical trial showing its vaccine for COVID-19 had an efficacy of 90 per cent exclusively on volunteers aged 55 and below, thereby excluding precisely the demographic most at risk from the disease. Shares in its business partner, the British-Swedish multinational pharmaceutical company AstraZeneca, dropped 6 perREAD MORE…READ MORE…